IQVIA (IQV) 10-Q 3 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 26, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	Q
Entity Registrant Name	Quintiles IMS Holdings, Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		246,181,560

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Service revenues	$ 1,136,423	$ 1,093,480	$ 3,411,509	$ 3,197,820
Reimbursed expenses	360,750	331,289	1,128,422	1,018,069
Total revenues	1,497,173	1,424,769	4,539,931	4,215,889
Costs of revenue, service costs	703,791	683,058	2,144,996	2,028,730
Costs of revenue, reimbursed expenses	360,750	331,289	1,128,422	1,018,069
Selling, general and administrative expenses	233,645	231,415	700,787	676,919
Restructuring costs	(467)	11,984	27,791	23,542
Merger related costs	3,747		12,689
Impairment charges	27,937		27,937
Income from operations	167,770	167,023	497,309	468,629
Interest income	(706)	(1,141)	(2,170)	(3,470)
Interest expense	24,505	25,429	72,947	76,256
Loss on extinguishment of debt				7,780
Other expense (income), net	1,667	(934)	3,370	7,864
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	142,304	143,669	423,162	380,199
Income tax expense	38,525	40,192	117,912	107,980
Income before equity in earnings (losses) of unconsolidated affiliates	103,779	103,477	305,250	272,219
Equity in earnings (losses) of unconsolidated affiliates	195	5,362	(952)	7,998
Net income	103,974	108,839	304,298	280,217
Net (income) loss attributable to non-controlling interests	(4,807)	2,447	(11,704)	2,418
Net income attributable to Quintiles IMS Holdings, Inc.	$ 99,167	$ 111,286	$ 292,594	$ 282,635
Earnings per share attributable to common stockholders:
Basic	$ 0.83	$ 0.91	$ 2.45	$ 2.28
Diluted	$ 0.82	$ 0.89	$ 2.41	$ 2.24
Weighted average common shares outstanding:
Basic	118,919	122,848	119,277	123,728
Diluted	121,156	125,339	121,371	126,443

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 103,974	$ 108,839	$ 304,298	$ 280,217
Comprehensive income adjustments:
Unrealized gains (losses) on available-for-sale securities, net of income taxes of $12, ($40), $5 and ($135)	18	(64)	7	(215)
Unrealized (losses) gains on derivative instruments, net of income taxes of $634, ($3,885), ($6,828) and ($4,598)	(256)	(8,440)	(19,524)	(8,660)
Defined benefit plan adjustments, net of income taxes of $45 and $116	(45)		139
Foreign currency translation, net of income taxes of ($1,359), ($1,563), ($6,162) and ($4,228)	(10,582)	(23,435)	(34,119)	(40,440)
Reclassification adjustments:
Losses on derivative instruments included in net income, net of income taxes of $1,713, $1,377, $4,144 and $4,623	5,949	2,612	13,450	9,950
Amortization of actuarial losses included in net income, net of income taxes of $82, $83, $233 and $251	147	142	428	429
Comprehensive income	99,205	79,654	264,679	241,281
Comprehensive (income) loss attributable to non-controlling interests	(1,920)	5,013	(1,695)	4,984
Comprehensive income attributable to Quintiles IMS Holdings, Inc.	$ 97,285	$ 84,667	$ 262,984	$ 246,265

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Unrealized gains (losses) on available-for-sale securities, income taxes	$ 12	$ (40)	$ 5	$ (135)
Unrealized (losses) gains on derivative instruments, income taxes	634	(3,885)	(6,828)	(4,598)
Defined benefit plan adjustments, income taxes	45		116
Foreign currency translation, income taxes	(1,359)	(1,563)	(6,162)	(4,228)
Losses on derivative instruments included in net income, income taxes	1,713	1,377	4,144	4,623
Amortization of actuarial losses included in net income, income taxes	$ 82	$ 83	$ 233	$ 251

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,209,677	$ 977,151
Restricted cash	2,547	2,478
Trade accounts receivable and unbilled services, net	1,207,503	1,165,749
Prepaid expenses	57,318	50,624
Deferred income taxes		100,978
Income taxes receivable	26,568	34,089
Investments in debt, equity and other securities	39,878
Other current assets and receivables	99,641	80,916
Total current assets	2,643,132	2,411,985
Property and equipment, net	184,189	188,393
Investments in debt, equity and other securities	8,000	32,911
Investments in unconsolidated affiliates	60,386	52,382
Goodwill	691,441	719,740
Other identifiable intangibles, net	346,816	368,106
Deferred income taxes	95,818	42,684
Deposits and other assets	99,020	110,115
Total assets	4,128,802	3,926,316
Current liabilities:
Accounts payable and accrued expenses	904,095	906,241
Unearned income	624,079	584,646
Income taxes payable	15,953	35,173
Current portion of long-term debt and obligations held under capital leases	48,500	48,513
Other current liabilities	27,321	19,603
Total current liabilities	1,619,948	1,594,176
Long-term debt and obligations held under capital leases, less current portion	2,387,114	2,419,293
Deferred income taxes	13,102	65,702
Other liabilities	190,565	182,826
Total liabilities	4,210,729	4,261,997
Commitments and contingencies
Stockholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 119,395 and 119,378 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	48,762	8,784
Accumulated deficit	(221,218)	(461,635)
Accumulated other comprehensive loss	(140,976)	(111,366)
Deficit attributable to Quintiles IMS Holdings, Inc.’s stockholders	(313,432)	(564,217)
Non-controlling interests	231,505	228,536
Total stockholders’ deficit	(81,927)	(335,681)
Total liabilities and stockholders’ deficit	$ 4,128,802	$ 3,926,316

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	119,395,000	119,378,000
Common stock, shares outstanding	119,395,000	119,378,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net income	$ 304,298	$ 280,217
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	98,368	93,224
Amortization of debt issuance costs and discount	5,058	7,485
Amortization of accumulated other comprehensive loss on terminated interest rate swaps	3,100	4,781
Stock-based compensation	34,357	28,702
Impairment of goodwill and identifiable intangible assets	27,937
Loss (earnings) from unconsolidated affiliates	5,417	(7,965)
(Benefit from) provision for deferred income taxes	(4,225)	23,252
Excess income tax benefits from stock-based award activities	(14,180)	(35,144)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	(16,343)	(170,279)
Change in other operating assets and liabilities	(30,840)	45,103
Net cash provided by operating activities	412,947	269,376
Investing activities:
Acquisition of property, equipment and software	(78,076)	(56,692)
Acquisition of businesses, net of cash acquired		31,001
Purchase of trading securities	(39,440)
Proceeds from corporate owned life insurance policies	20,938
Proceeds from sale of cost method investments	26,042
Investments in unconsolidated affiliates, net of payments received	(13,235)	(4,840)
Termination of interest rate swaps		(10,981)
Other	1,921	2,111
Net cash used in investing activities	(81,850)	(39,401)
Financing activities:
Proceeds from issuance of debt		2,248,500
Payment of debt issuance costs		(22,028)
Repayment of debt and principal payments on capital lease obligations	(37,616)	(2,048,211)
Stock issued under employee stock purchase and option plans	42,930	58,323
Repurchase of common stock	(97,637)	(250,000)
Excess income tax benefits from stock-based award activities	14,180	35,144
Net cash (used in) provided by financing activities	(78,143)	21,728
Effect of foreign currency exchange rate changes on cash	(20,428)	(37,257)
Increase in cash and cash equivalents	232,526	214,446
Cash and cash equivalents at beginning of period	977,151	867,358
Cash and cash equivalents at end of period	$ 1,209,677	$ 1,081,804

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Unaudited Interim Financial Information On October 3, 2016, Quintiles Transnational Holdings Inc. (“Quintiles”) completed its previously announced merger of equals transaction (the “Merger”) with IMS Health Holdings, Inc. (“IMS Health”). Pursuant to the terms of the merger agreement dated as of May 3, 2016 between Quintiles and IMS Health (the “Merger Agreement”), IMS Health was merged with and into Quintiles, and the separate corporate existence of IMS Health ceased, with Quintiles continuing as the surviving corporation (the “Surviving Corporation”). The Surviving Corporation changed its name to Quintiles IMS Holdings, Inc. (the “Company”). At the effective time of the Merger, each issued and outstanding share of IMS Health common stock, par value $0.01 per share (“IMS Health common stock”), was automatically converted into 0.3840 of a share of the Company’s common stock, par value $0.01 per share. Because the closing of the Merger occurred subsequent to the date of these financial statements, IMS Health’s results of operations are not included in the accompanying condensed consolidated financial statements. See Note 18 for additional information regarding the Merger. The accompanying unaudited condensed consolidated financial statements of Quintiles IMS Holdings, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of stockholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification. Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In August 2016, the FASB issued new accounting guidance which eliminates the diversity in practice related to the cash flow classification of certain cash receipts and payments including debt prepayment or extinguishment payments, payments upon maturity of a zero coupon bond, payment of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions received from certain equity method investees, and cash flows related to beneficial interests obtained in a financial asset securitization. The new guidance designates the appropriate cash flow statement classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. This new accounting guidance will be effective for the Company on January 1, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee stock-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess income tax benefits on the statement of cash flows. The Company expects to adopt this new accounting guidance as required on January 1, 2017. Under the new accounting guidance, excess income tax benefits related to stock-based awards will be reflected as a reduction of income tax expense on the statements of income and as cash provided from operating activities. Under existing guidance, these tax benefits are reflected directly in additional paid-in capital and as cash provided from financing activities. The Company recognized $14.2 million of such income tax benefits in the nine months ended September 30, 2016. The Company does not expect the adoption of this new accounting guidance to impact the recognition of its stock-based compensation expense or its presentation of cash flows related to employee taxes paid for withheld shares. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of this new accounting guidance is not expected to have a material effect on the Company’s consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with clients. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to clients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with clients. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation

Employee Stock Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Stock Compensation	2. Employee Stock Compensation The Company granted the following number of stock-based awards: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Stock options — 10,000 783,700 986,900 Stock appreciation rights 15,200 — 40,400 176,200 Restricted stock awards 86,356 — 86,356 — Restricted stock units 120,845 2,553 494,681 239,763 Performance units — — 119,839 51,977 The restricted stock awards issued during 2016 will vest in three equal quarterly installments on June 30, September 30 and December 31, 2017. The Company had the following number of stock-based awards outstanding: September 30, 2016 December 31, 2015 Stock options 5,934,854 6,647,999 Stock appreciation rights 512,876 530,701 Restricted stock awards 86,356 — Restricted stock units 777,331 359,553 Performance units 164,886 49,667 All performance units outstanding at the date of the Merger were converted into restricted stock units with service based vesting requirements. The Company used the following assumptions when estimating the value of the stock-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Expected volatility 26 – 29% 26 –36% 26 – 30% 26 – 41% Weighted average expected volatility 27% 30% 28% 35% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.96 – 1.36% 1.08 – 1.83% 0.80 – 1.57% 1.06 – 2.00% The Company issued 89,425 shares and 90,079 shares of common stock for purchases under its employee stock purchase plan during the nine months ended September 30, 2016 and 2015, respectively. The Company recognized stock-based compensation expense of $15.6 million and $8.4 million during the three months ended September 30, 2016 and 2015, respectively, and $34.4 million and $28.7 million during the nine months ended September 30, 2016 and 2015, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	9 Months Ended
	Sep. 30, 2016
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	3. Concentration of Credit Risk No client accounted for 10% or more of consolidated service revenues for the three and nine months ended September 30, 2016 or 2015.

Accounts Receivable and Unbille

Accounts Receivable and Unbilled Services	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	4. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of the following (in thousands): September 30, 2016 December 31, 2015 Trade: Billed $ 552,326 $ 553,652 Unbilled services 660,798 614,381 1,213,124 1,168,033 Allowance for doubtful accounts (5,621 ) (2,284 ) $ 1,207,503 $ 1,165,749

Investments-Debt, Equity and Ot

Investments-Debt, Equity and Other Securities	9 Months Ended
	Sep. 30, 2016
Investments Debt And Equity Securities [Abstract]
Investments-Debt, Equity and Other Securities	5. Investments – Debt, Equity and Other Securities Current The Company’s short-term investments in debt, equity and other securities consist primarily of trading investments in mutual funds and are measured at fair value with realized and unrealized gains and losses recorded in other expense (income), net on the accompanying condensed consolidated statements of income. Net realized and unrealized gains were approximately $1.7 million and $2.4 million during the three and nine months ended September 30, 2016, respectively. Long-term The Company’s long-term investments in debt, equity and other securities consist primarily of cost method investments. The Company is party to a joint venture with the Samsung Group to provide biopharmaceutical contract manufacturing services in South Korea. The Company’s investment in the joint venture totaled $27.2 million at December 31, 2015. During the second quarter of 2016, the Company exercised its right to sell a portion of its ownership interest in the joint venture to the Samsung Group in exchange for approximately $26.0 million. As of September 30, 2016, the Company’s investment in the joint venture totaled approximately $1.2 million (representing an ownership interest of less than 1%). In December 2011, the Company and Intarcia Therapeutics (“Intarcia”) entered into an alliance to develop a new therapy for type 2 diabetes whereby Intarcia will use the Company to conduct Phase III pivotal clinical trials and a cardiovascular outcomes clinical trial. Under the alliance, the Company acquired $5.0 million of preferred stock of Intarcia.

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2016
Variable Interest Entity Disclosure [Abstract]
Variable Interest Entities	6. Variable Interest Entities As of September 30, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 41,233 $ 48,094 NovaQuest Pharma Opportunities Fund IV, L.P. 8,200 19,951 $ 49,433 $ 68,045 The Company has committed to invest up to $50 million as a limited partner in NovaQuest Pharma Opportunities Fund III, L.P. (“Fund III”). As of September 30, 2016, the Company has funded approximately $43.1 million and has approximately $6.9 million of remaining funding commitments. As of September 30, 2016 and December 31, 2015, the Company had a 10.9% ownership interest in Fund III. The Company’s maximum exposure to loss on Fund III is limited to its investment and remaining funding commitments. The Company has committed to invest up to $20 million as a limited partner in NovaQuest Pharma Opportunities Fund IV, L.P. (“Fund IV”). As of September 30, 2016, the Company has funded approximately $8.2 million and has approximately $11.8 million of remaining funding commitments. As of September 30, 2016 and December 31, 2015, the Company had a 2.3% ownership interest in Fund IV. The Company’s maximum exposure to loss on Fund IV is limited to its investment and remaining funding commitments. The Company has determined that Fund III and Fund IV (collectively “the Funds”) are VIEs but that the Company is not the primary beneficiary as it does not have a controlling financial interest in either of the Funds. Although the Company does not have a controlling financial interest in either of the Funds, the Company has determined that it has the ability to exercise significant influence. Accordingly, the Company accounts for its investments in the Funds under the equity method of accounting and records its pro rata share of the Funds’ earnings and losses in equity in (losses) earnings of unconsolidated affiliates on the accompanying condensed consolidated statements of income. The investment assets of unconsolidated VIEs are included in investments in and advances to unconsolidated affiliates

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	7. Goodwill The following is a summary of goodwill by segment for the nine months ended September 30, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impairment — (23,147 ) (23,147 ) Impact of foreign currency fluctuations and other (9,765 ) 4,613 (5,152 ) Balance as of September 30, 2016 $ 592,341 $ 99,100 $ 691,441 As of September 30, 2016, accumulated impairment losses were $23.1 million. See Note 13 for additional information regarding impairment losses.

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	8. Derivatives As of September 30, 2016, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes. As of September 30, 2016, the Company had nine open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2016 and the first six months of 2017 with notional amounts totaling $118.8 million. These contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the remainder of 2016 and the first six months of 2017. These transactions are accounted for as cash flow hedges, as such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in AOCI. For accounting purposes these hedges are deemed to be highly effective. As of September 30, 2016 and December 31, 2015, the Company had recorded gross unrealized losses of $8.6 million and $5.2 million, respectively, related to foreign exchange forward contracts. Upon expiration of the hedge instruments in 2016 and the first six months of 2017, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings. The unrealized losses are included in other current liabilities on the accompanying condensed consolidated balance sheets as of September 30, 2016 and December 31, 2015. On June 3, 2015, the Company entered into seven forward starting interest rate swaps with a notional value of $440.0 million in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps began accruing on June 30, 2016 and the interest rate swaps expire between March 31, 2017 and March 31, 2020. The critical terms of the interest rate swaps are substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and for accounting purposes these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in AOCI. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.1% plus the applicable margin on the affected borrowings. These interest rate swaps will result in a total debt mix of approximately 50% fixed rate debt and 50% variable rate debt. The Company expects that $5.3 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.1% fixed rate of interest incurred over the next 12 months as the underlying net payments are settled. The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification September 30, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 8,564 $ 5,194 Interest rate swaps Other current liabilities $ 14,186 $ 5,698 The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Foreign exchange forward contracts $ 3,668 $ (3,795 ) $ (3,370 ) $ 2,594 Interest rate swaps 4,372 (4,541 ) (5,388 ) (1,279 ) Total $ 8,040 $ (8,336 ) $ (8,758 ) $ 1,315

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of September 30, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 39,878 $ — $ — $ 39,878 Available-for-sale securities 408 — — 408 Total $ 40,286 $ — $ — $ 40,286 Liabilities: Foreign exchange forward contracts $ — $ 8,564 $ — $ 8,564 Interest rate swaps — 14,186 — 14,186 Contingent consideration — — 4,500 4,500 Total $ — $ 22,750 $ 4,500 $ 27,250 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs. Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 126 6,002 Balance as of September 30 $ 4,500 $ 7,454 The revaluations for the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income. Non-recurring Fair Value Measurements Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs. See Note 13 for additional information. As of September 30, 2016, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $1,106.0 million and were identified as Level 3. These assets are comprised of cost and equity method investments of $67.8 million, goodwill of $691.4 million and other identifiable intangibles, net of $346.8 million. The estimated fair value of the Company’s long-term debt approximates its carrying value as of September 30, 2016 and December 31, 2015. The estimated fair value of the long-term debt is primarily based on rates in which the debt is traded among banks.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Deficit	10. Stockholders’ Deficit Equity Repurchase Program During the nine months ended September 30, 2016, the Company repurchased 1,486,679 shares of its common stock under a previously approved equity repurchase program (the “Repurchase Program”) at an average market price per share of $65.67 for an aggregate purchase price of $97.6 million. From the plan’s inception in October 2013 through September 30, 2016, the Company has repurchased a total of $678.2 million of its securities under the Repurchase Program, consisting of $59.1 million of stock options and $619.1 million of common stock. As of September 30, 2016, the Company has remaining authorization to repurchase up to $46.8 million of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. See Note 18 for additional information. Non-controlling Interests Below is a summary of non-controlling interests for the nine months ended September 30 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Investment by non-controlling interest 1,274 231,030 Comprehensive income (loss): Net income (loss) 11,704 (2,418 ) Foreign currency adjustments, net of income tax (10,009 ) (2,566 ) Balance as of September 30 $ 231,505 $ 226,095

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Restructuring	11. Restructuring 2016 Plan During 2016, the Company’s Board of Directors (the “Board”) approved a restructuring plan for approximately $41 million, primarily for severance and other exit costs, to align its resources and reduce overcapacity. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs. 2015 Plans During 2015 approved a restructuring plan for approximately $30.0 million to align the Company’s resources and reduce overcapacity. These actions are expected to continue throughout 2016, and are expected to consist of severance, facility closure and other exit-related costs. Also, in connection with consummating the joint venture transaction with Quest Diagnostics Incorporated, during 2015, a restructuring plan was approved to reduce facility overcapacity and eliminate redundant roles. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs of approximately $14.0 million. Since the start of this plan in 2015, the Company has recognized approximately $9.6 million of restructuring costs related to this plan for activities in the Product Development segment. The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 26,470 1,321 27,791 Payments (23,419 ) (1,658 ) (25,077 ) Foreign currency translation and other (1,858 ) 827 (1,031 ) Balance at September 30, 2016 $ 13,372 $ 1,875 $ 15,247 Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects the majority of the restructuring accruals at September 30, 2016 will be paid in 2016 and 2017.

Merger Related Costs

Merger Related Costs	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Merger Related Costs	12. Merger Related Costs Merger related costs include the direct and incremental costs associated with the Merger such as investment banking, legal, accounting and consulting fees. The Company recognized approximately $3.7 million and $12.7 million of such costs during the three and nine months ended September 30, 2016, respectively.

Impairment Charges

Impairment Charges	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment Charges	13. Impairment Charges During the third quarter of 2016 as part of its annual impairment review, the Company determined that it was more likely than not that the fair value of its Encore reporting unit was less than its carrying amount due to certain strategic initiatives not performing as expected resulting in a decline in service revenues. The Company performed a quantitative analysis using the present value of the estimated future cash flows, which confirmed that the Encore reporting unit’s goodwill was impaired. The Company proceeded to perform step two of its Encore goodwill impairment assessment which resulted in the recognition of impairment losses of $23.1 million and $4.8 million for other-than-temporary declines in the fair value of goodwill and identifiable intangible assets, respectively.

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	14. Employee Benefit Plans Defined Benefit Plans The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Service cost $ 4,491 $ 3,554 $ 13,122 $ 11,419 Interest cost 891 867 2,741 2,600 Expected return on plan assets (805 ) (869 ) (2,549 ) (2,583 ) Amortization of actuarial losses 229 225 661 680 $ 4,806 $ 3,777 $ 13,975 $ 12,116 Other As of September 30, 2016 and December 31, 2015, the Company had a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $2.4 million and $3.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions. During the first nine months of 2016, the Company recognized approximately $513,000 of net reversals related to these cost reduction programs in the Product Development segment, primarily as a result of affected individuals transferring into other positions within the Company. The Company expects the majority of the severance accrual at September 30, 2016 will be paid in 2017. The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (513 ) Payments (344 ) Foreign currency translation (45 ) Balance at September 30, 2016 $ 2,435

Comprehensive Income

Comprehensive Income	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Comprehensive Income	15. Comprehensive Income Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications (30,272 ) 12 (26,352 ) 255 12,869 (43,488 ) Reclassification adjustments — — 17,594 661 (4,377 ) 13,878 Balance at September 30, 2016 $ (147,102 ) $ (696 ) $ (22,750 ) $ (12,348 ) $ 41,920 $ (140,976 ) Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three Months Ended September 30, Nine Months Ended September 30, Reclassification Adjustments Line Item 2016 2015 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ 1,600 $ 3,130 $ 4,700 $ 9,233 Foreign exchange forward contracts Service revenues 6,062 859 12,894 5,340 Total before income taxes 7,662 3,989 17,594 14,573 Income tax benefit 1,713 1,377 4,144 4,623 Total net of income taxes $ 5,949 $ 2,612 $ 13,450 $ 9,950 Defined benefit plans: Amortization of actuarial losses See Note 14 $ 229 $ 225 $ 661 $ 680 Total before income taxes 229 225 661 680 Income tax benefit 82 83 233 251 Total net of income taxes $ 147 $ 142 $ 428 $ 429

Segments

Segments	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segments	16. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical clients engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical clients and research, analytics, real-world and late phase research, and other services to both biopharmaceutical clients and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation, and expenses for corporate overhead functions such as senior leadership, finance, human resources, information technology, facilities and legal. The Company does not allocate restructuring costs, merger related costs or impairment charges to its segments. Information presented below is in thousands: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Service revenues Product Development $ 874,312 $ 810,045 $ 2,601,909 $ 2,345,971 Integrated Healthcare Services 262,111 283,435 809,600 851,849 Total service revenues 1,136,423 1,093,480 3,411,509 3,197,820 Costs of revenue, service costs Product Development 499,638 461,858 1,513,353 1,352,730 Integrated Healthcare Services 204,153 221,200 631,643 676,000 Total costs of revenue, service costs 703,791 683,058 2,144,996 2,028,730 Selling, general and administrative expenses Product Development 167,732 166,758 505,378 478,643 Integrated Healthcare Services 35,172 38,186 111,422 114,953 General corporate and unallocated 30,741 26,471 83,987 83,323 Total selling, general and administrative expenses 233,645 231,415 700,787 676,919 Income from operations Product Development 206,942 181,429 583,178 514,598 Integrated Healthcare Services 22,786 24,049 66,535 60,896 General corporate and unallocated (30,741 ) (26,471 ) (83,987 ) (83,323 ) Restructuring costs 467 (11,984 ) (27,791 ) (23,542 ) Merger related costs (3,747 ) — (12,689 ) — Impairment charges (27,937 ) — (27,937 ) — Total income from operations $ 167,770 $ 167,023 $ 497,309 $ 468,629 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Depreciation and amortization expense Product Development $ 29,593 $ 26,681 $ 82,575 $ 74,110 Integrated Healthcare Services 4,020 5,118 12,549 15,497 General corporate and unallocated 990 1,085 3,244 3,617 Total depreciation and amortization expense $ 34,603 $ 32,884 $ 98,368 $ 93,224

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	17. Earnings Per Share The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share if they are subject to performance conditions or if the effect of including such stock-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Shares subject to performance conditions 198 51 161 40 Shares subject to anti-dilutive stock-based awards 718 952 1,198 1,036 Total shares excluded from diluted earnings per share 916 1,003 1,359 1,076 The vesting of performance units is contingent upon the achievement of certain performance targets. The performance units are not included in diluted earnings per share until the performance targets have been met. Stock-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Merger On October 3, 2016, pursuant to the terms of the Merger Agreement, IMS Health merged with and into Quintiles, with Quintiles continuing as the Surviving Corporation. The combination of Quintiles and IMS Health capabilities and resources creates an information and technology enabled healthcare service provider with a full suite of end-to-end clinical and commercial offerings. The Merger will be accounted for as a business combination with Quintiles considered the accounting and the legal acquirer. At the effective time of the Merger, IMS Health common stock was automatically converted into 0.3840 of a share of the Company’s common stock. In addition, IMS Health equity awards held by current employees and certain members of the former IMS Health board of directors were converted into the Company’s equity awards after giving effect to the exchange ratio. The terms of these awards, including vesting provisions, are substantially consistent to those of the historical IMS Health equity awards. All of the Company’s and IMS Health’s performance units outstanding at the date of the Merger were converted into restricted stock units with service based vesting requirements. The merger consideration is estimated to be approximately $10.4 billion (based on the closing price of the Company’s common stock on October 3, 2016), and consists of the fair value of the Company’s common stock issued (approximately 126.6 million shares) in exchange for the IMS Health common stock as well as the fair value of the vested portion of the converted IMS Health equity awards. The calculation of the estimated consideration is subject to change as the Company is in the process of completing the final analysis of certain components of the purchase price. The Company has not completed the detailed valuations necessary to determine the estimated fair value of the assets acquired and the liabilities assumed. The Company estimates that $10 billion of fair value will be assigned to acquired assets, including $10 billion of identifiable tangible and intangible assets, and $9 billion of liabilities assumed, with the remainder representing approximately $9 billion of goodwill. Goodwill, primarily attributable to the assembled workforce of IMS Health and the expected synergies, will not be deductible for income tax purposes. The Company’s assessment of fair value and the purchase price accounting are preliminary and subject to change upon completion. The following unaudited pro forma information presents the financial results as if the acquisition of IMS Health had occurred on January 1, 2015 with pro forma adjustments to give effect to i) an increase in depreciation and amortization expense for fair value adjustments of property, plant and equipment and intangible assets, ii) an increase in stock-based compensation expense resulting from the exchange of the vested IMS Health equity awards for the Company’s equity awards, iii) to present transaction costs in the 2015 periods, and iv) the related income tax effects. The pro forma results do not include any anticipated cost synergies, costs or other effects of the planned integration of IMS Health. Accordingly, such pro forma amounts are not necessarily indicative of the results that actually would have occurred for the periods presented below had the IMS Health acquisition been completed on January 1, 2015, nor are they indicative of the future operating results of the Company. The following table summarizes the pro forma results (in thousands, except earnings per share): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Product and service revenues $ 1,926,000 $ 1,828,000 $ 5,775,000 $ 5,305,000 Reimbursed expenses 361,000 331,000 1,128,000 1,018,000 Total revenues $ 2,287,000 $ 2,159,000 $ 6,903,000 $ 6,323,000 Net income attributable to Quintiles IMS Holdings, Inc. $ 88,000 $ 113,000 $ 255,000 $ 525,000 Earnings per share attributable to common stockholders: Basic $ 0.36 $ 0.45 $ 1.04 $ 2.10 Diluted $ 0.35 $ 0.44 $ 1.02 $ 2.04 Financing Transactions On October 3, 2016, the Company repaid in full ($1,389.4 million) the term loans outstanding under the Quintiles Transnational Corp. senior secured credit facilities. These redemptions were funded by the proceeds of new debt issued by IMS Health on September 28, 2016 and therefore assumed by the Company upon closing of the Merger. This new debt issued on September 28, 2016, totaling principal amount of $1,750 million, consists of (i) $1,050 million of 5% senior notes due 2026 (the “5% Dollar Notes”) and (ii) €625 million of 3.5% senior notes due 2024 (the “3.5% Euro Notes” and, together with the 5% Dollar Notes, the “2016 Notes”). The 2016 Notes are unsecured obligations. The 5% Dollar Notes will mature on October 15, 2026 and will bear interest at the rate of 5% per year, with interest payable semi-annually on April 15 and October 15 of each year, beginning on April 15, 2017. The 3.5% Euro Notes will mature on October 15, 2024 and will bear interest at the rate of 3.5% per year, with interest payable semi-annually on April 15 and October 15 of each year, beginning on April 15, 2017. On October 3, 2016, the Company refinanced the term A loans due 2019 (approximately $884 million) assumed in the Merger with a term A loan facility due in 2021 for an aggregate principal amount of approximately $1,350 million comprised of both U.S. Dollar denominated term A loans and Euro denominated term A loans. Additionally, the revolving credit facility was refinanced to an aggregate principal amount equal to $1,000 million comprised of a $450 million senior secured revolving facility available in U.S. Dollars, a $400 million senior secured revolving facility available in U.S. Dollars, Euros, Swiss Francs and other foreign currencies and a $150 million senior secured revolving facility available in U.S. Dollars and Yen. Under certain circumstances, the maturity date of the term A loans and the senior secured revolving facility may be accelerated to 2020. The additional proceeds were used, in part, to fund the redemption of the $500 million of 6% Senior Notes due 2020 assumed in the Merger which occurred on November 1, 2016. Equity Repurchase Program On November 1, 2016, the Board increased its stock repurchase authorization under the previously approved equity repurchase program by $1.5 billion. The total authorization available for stock repurchases is approximately $1,546.8 million. The equity repurchase program does not obligate the Company to acquire any particular amount of common stock, and may be modified, extended, suspended or discontinued at any time. Repatriation of Indefinitely Reinvested Earnings As a result of the merger with IMS Health, the Company is currently evaluating the domestic and foreign cash positions for the Surviving Corporation. Absent the merger and as of September 30, 2016, the earnings of most of the Company's foreign subsidiaries are considered indefinitely reinvested outside the United States. If the Surviving Corporation determines that repatriation of some or all of these indefinitely reinvested earnings held outside of the United States may be needed to fund the stock repurchase or other merger related items, it could incur an additional income tax liability of up to an estimated $175.0 million.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information On October 3, 2016, Quintiles Transnational Holdings Inc. (“Quintiles”) completed its previously announced merger of equals transaction (the “Merger”) with IMS Health Holdings, Inc. (“IMS Health”). Pursuant to the terms of the merger agreement dated as of May 3, 2016 between Quintiles and IMS Health (the “Merger Agreement”), IMS Health was merged with and into Quintiles, and the separate corporate existence of IMS Health ceased, with Quintiles continuing as the surviving corporation (the “Surviving Corporation”). The Surviving Corporation changed its name to Quintiles IMS Holdings, Inc. (the “Company”). At the effective time of the Merger, each issued and outstanding share of IMS Health common stock, par value $0.01 per share (“IMS Health common stock”), was automatically converted into 0.3840 of a share of the Company’s common stock, par value $0.01 per share. Because the closing of the Merger occurred subsequent to the date of these financial statements, IMS Health’s results of operations are not included in the accompanying condensed consolidated financial statements. See Note 18 for additional information regarding the Merger. The accompanying unaudited condensed consolidated financial statements of Quintiles IMS Holdings, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Investments in Marketable Securities	Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other expense (income), net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of stockholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In August 2016, the FASB issued new accounting guidance which eliminates the diversity in practice related to the cash flow classification of certain cash receipts and payments including debt prepayment or extinguishment payments, payments upon maturity of a zero coupon bond, payment of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions received from certain equity method investees, and cash flows related to beneficial interests obtained in a financial asset securitization. The new guidance designates the appropriate cash flow statement classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. This new accounting guidance will be effective for the Company on January 1, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee stock-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess income tax benefits on the statement of cash flows. The Company expects to adopt this new accounting guidance as required on January 1, 2017. Under the new accounting guidance, excess income tax benefits related to stock-based awards will be reflected as a reduction of income tax expense on the statements of income and as cash provided from operating activities. Under existing guidance, these tax benefits are reflected directly in additional paid-in capital and as cash provided from financing activities. The Company recognized $14.2 million of such income tax benefits in the nine months ended September 30, 2016. The Company does not expect the adoption of this new accounting guidance to impact the recognition of its stock-based compensation expense or its presentation of cash flows related to employee taxes paid for withheld shares. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of this new accounting guidance is not expected to have a material effect on the Company’s consolidated financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with clients. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to clients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with clients. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation (Ta

Employee Stock Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Number of Stock-Based Awards Granted and Outstanding	The Company granted the following number of stock-based awards: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Stock options — 10,000 783,700 986,900 Stock appreciation rights 15,200 — 40,400 176,200 Restricted stock awards 86,356 — 86,356 — Restricted stock units 120,845 2,553 494,681 239,763 Performance units — — 119,839 51,977 The Company had the following number of stock-based awards outstanding: September 30, 2016 December 31, 2015 Stock options 5,934,854 6,647,999 Stock appreciation rights 512,876 530,701 Restricted stock awards 86,356 — Restricted stock units 777,331 359,553 Performance units 164,886 49,667
Assumptions Used to Estimate Value of Stock-Based Compensation for Stock Options and Stock Appreciation Rights Issued	The Company used the following assumptions when estimating the value of the stock-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Expected volatility 26 – 29% 26 –36% 26 – 30% 26 – 41% Weighted average expected volatility 27% 30% 28% 35% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.96 – 1.36% 1.08 – 1.83% 0.80 – 1.57% 1.06 – 2.00%

Accounts Receivable and Unbil28

Accounts Receivable and Unbilled Services (Tables)	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands): September 30, 2016 December 31, 2015 Trade: Billed $ 552,326 $ 553,652 Unbilled services 660,798 614,381 1,213,124 1,168,033 Allowance for doubtful accounts (5,621 ) (2,284 ) $ 1,207,503 $ 1,165,749

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2016
Variable Interest Entity Disclosure [Abstract]
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss	As of September 30, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 41,233 $ 48,094 NovaQuest Pharma Opportunities Fund IV, L.P. 8,200 19,951 $ 49,433 $ 68,045

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the nine months ended September 30, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impairment — (23,147 ) (23,147 ) Impact of foreign currency fluctuations and other (9,765 ) 4,613 (5,152 ) Balance as of September 30, 2016 $ 592,341 $ 99,100 $ 691,441

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification September 30, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 8,564 $ 5,194 Interest rate swaps Other current liabilities $ 14,186 $ 5,698
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Foreign exchange forward contracts $ 3,668 $ (3,795 ) $ (3,370 ) $ 2,594 Interest rate swaps 4,372 (4,541 ) (5,388 ) (1,279 ) Total $ 8,040 $ (8,336 ) $ (8,758 ) $ 1,315

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of September 30, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 39,878 $ — $ — $ 39,878 Available-for-sale securities 408 — — 408 Total $ 40,286 $ — $ — $ 40,286 Liabilities: Foreign exchange forward contracts $ — $ 8,564 $ — $ 8,564 Interest rate swaps — 14,186 — 14,186 Contingent consideration — — 4,500 4,500 Total $ — $ 22,750 $ 4,500 $ 27,250
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the nine months ended September 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 126 6,002 Balance as of September 30 $ 4,500 $ 7,454

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Non-controlling Interests	Below is a summary of non-controlling interests for the nine months ended September 30 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Investment by non-controlling interest 1,274 231,030 Comprehensive income (loss): Net income (loss) 11,704 (2,418 ) Foreign currency adjustments, net of income tax (10,009 ) (2,566 ) Balance as of September 30 $ 231,505 $ 226,095

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 26,470 1,321 27,791 Payments (23,419 ) (1,658 ) (25,077 ) Foreign currency translation and other (1,858 ) 827 (1,031 ) Balance at September 30, 2016 $ 13,372 $ 1,875 $ 15,247

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2016
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Service cost $ 4,491 $ 3,554 $ 13,122 $ 11,419 Interest cost 891 867 2,741 2,600 Expected return on plan assets (805 ) (869 ) (2,549 ) (2,583 ) Amortization of actuarial losses 229 225 661 680 $ 4,806 $ 3,777 $ 13,975 $ 12,116
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (513 ) Payments (344 ) Foreign currency translation (45 ) Balance at September 30, 2016 $ 2,435

Comprehensive Income (Tables)

Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications (30,272 ) 12 (26,352 ) 255 12,869 (43,488 ) Reclassification adjustments — — 17,594 661 (4,377 ) 13,878 Balance at September 30, 2016 $ (147,102 ) $ (696 ) $ (22,750 ) $ (12,348 ) $ 41,920 $ (140,976 )
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three Months Ended September 30, Nine Months Ended September 30, Reclassification Adjustments Line Item 2016 2015 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ 1,600 $ 3,130 $ 4,700 $ 9,233 Foreign exchange forward contracts Service revenues 6,062 859 12,894 5,340 Total before income taxes 7,662 3,989 17,594 14,573 Income tax benefit 1,713 1,377 4,144 4,623 Total net of income taxes $ 5,949 $ 2,612 $ 13,450 $ 9,950 Defined benefit plans: Amortization of actuarial losses See Note 14 $ 229 $ 225 $ 661 $ 680 Total before income taxes 229 225 661 680 Income tax benefit 82 83 233 251 Total net of income taxes $ 147 $ 142 $ 428 $ 429

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Service revenues Product Development $ 874,312 $ 810,045 $ 2,601,909 $ 2,345,971 Integrated Healthcare Services 262,111 283,435 809,600 851,849 Total service revenues 1,136,423 1,093,480 3,411,509 3,197,820 Costs of revenue, service costs Product Development 499,638 461,858 1,513,353 1,352,730 Integrated Healthcare Services 204,153 221,200 631,643 676,000 Total costs of revenue, service costs 703,791 683,058 2,144,996 2,028,730 Selling, general and administrative expenses Product Development 167,732 166,758 505,378 478,643 Integrated Healthcare Services 35,172 38,186 111,422 114,953 General corporate and unallocated 30,741 26,471 83,987 83,323 Total selling, general and administrative expenses 233,645 231,415 700,787 676,919 Income from operations Product Development 206,942 181,429 583,178 514,598 Integrated Healthcare Services 22,786 24,049 66,535 60,896 General corporate and unallocated (30,741 ) (26,471 ) (83,987 ) (83,323 ) Restructuring costs 467 (11,984 ) (27,791 ) (23,542 ) Merger related costs (3,747 ) — (12,689 ) — Impairment charges (27,937 ) — (27,937 ) — Total income from operations $ 167,770 $ 167,023 $ 497,309 $ 468,629
Depreciation and Amortization Expense	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Depreciation and amortization expense Product Development $ 29,593 $ 26,681 $ 82,575 $ 74,110 Integrated Healthcare Services 4,020 5,118 12,549 15,497 General corporate and unallocated 990 1,085 3,244 3,617 Total depreciation and amortization expense $ 34,603 $ 32,884 $ 98,368 $ 93,224

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share if they are subject to performance conditions or if the effect of including such stock-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Shares subject to performance conditions 198 51 161 40 Shares subject to anti-dilutive stock-based awards 718 952 1,198 1,036 Total shares excluded from diluted earnings per share 916 1,003 1,359 1,076

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2016
IMS Health Holdings, Inc. [Member]
Summary of Pro Forma Results	The following table summarizes the pro forma results (in thousands, except earnings per share): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Product and service revenues $ 1,926,000 $ 1,828,000 $ 5,775,000 $ 5,305,000 Reimbursed expenses 361,000 331,000 1,128,000 1,018,000 Total revenues $ 2,287,000 $ 2,159,000 $ 6,903,000 $ 6,323,000 Net income attributable to Quintiles IMS Holdings, Inc. $ 88,000 $ 113,000 $ 255,000 $ 525,000 Earnings per share attributable to common stockholders: Basic $ 0.36 $ 0.45 $ 1.04 $ 2.10 Diluted $ 0.35 $ 0.44 $ 1.02 $ 2.04

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Oct. 03, 2016	Sep. 30, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value		$ 0.01	$ 0.01
Adoption of New Accounting Guidance [Member]
Summary Of Significant Accounting Policies [Line Items]
Excess income tax benefits recognized from share-based awards		$ 14.2
Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value	$ 0.01
Subsequent Event [Member] | IMS Health Holdings, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Business acquisition through merger, acquisition date	Oct. 3, 2016
Business acquisition through merger, agreement date	May 3, 2016
Common stock, par value	$ 0.01
Subsequent Event [Member] | IMS Health Holdings, Inc. [Member] | Common Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Merger agreement, stock for stock exchange ratio	38.40%

Employee Stock Compensation - S

Employee Stock Compensation - Schedule of Number of Stock-Based Awards Granted and Outstanding (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		10,000	783,700	986,900
Stock options outstanding	5,934,854		5,934,854		6,647,999
Stock Appreciation Rights Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	15,200		40,400	176,200
Equity Instruments Other than Options, Outstanding	512,876		512,876		530,701
Restricted Stock Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	86,356		86,356
Equity Instruments Other than Options, Outstanding	86,356		86,356
Restricted Stock Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	120,845	2,553	494,681	239,763
Equity Instruments Other than Options, Outstanding	777,331		777,331		359,553
Performance Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants			119,839	51,977
Equity Instruments Other than Options, Outstanding	164,886		164,886		49,667

Employee Stock Compensation - A

Employee Stock Compensation - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)Installmentshares	Sep. 30, 2015USD ($)shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $	$ 15,600	$ 8,400	$ 34,357	$ 28,702
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued for purchases under employee stock purchase plan | shares			89,425	90,079
Restricted Stock Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equal quarterly award vesting installments | Installment			3
First Installment [Member] | Restricted Stock Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting date			Jun. 30, 2017
Second Installment [Member] | Restricted Stock Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting date			Sep. 30, 2017
Third Installment [Member] | Restricted Stock Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting date			Dec. 31, 2017

Employee Stock Compensation -43

Employee Stock Compensation - Assumptions Used to Estimate Value of Stock-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	26.00%	26.00%	26.00%	26.00%
Expected volatility, Maximum	29.00%	36.00%	30.00%	41.00%
Weighted average expected volatility	27.00%	30.00%	28.00%	35.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate, Minimum	0.96%	1.08%	0.80%	1.06%
Risk-free interest rate, Maximum	1.36%	1.83%	1.57%	2.00%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	3 years 7 months 6 days	3 years 8 months 12 days	3 years 7 months 6 days	3 years 8 months 12 days
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	6 years 7 months 6 days	6 years 8 months 12 days	6 years 7 months 6 days	6 years 8 months 12 days

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Risks And Uncertainties [Abstract]
Number of clients served	0	0	0	0

Accounts Receivable and Unbil45

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Trade:
Billed	$ 552,326	$ 553,652
Unbilled services	660,798	614,381
Trade accounts receivable and unbilled services, gross	1,213,124	1,168,033
Allowance for doubtful accounts	(5,621)	(2,284)
Trade accounts receivable and unbilled services, net	$ 1,207,503	$ 1,165,749

Investments - Debt, Equity and

Investments - Debt, Equity and Other Securities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Line Items]
Net realized and unrealized gains	$ 1.7		$ 2.4
Investment in joint venture	1.2		1.2	$ 27.2
Proceeds from sale of ownership interest in joint venture		$ 26
Preferred stock acquired from Intarcia	$ 5		$ 5
Maximum [Member]
Investments Debt And Equity Securities [Line Items]
Non controlling interest percentage in exchange of investment in joint venture	1.00%		1.00%

Variable Interest Entities - Su

Variable Interest Entities - Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss (Detail)	Sep. 30, 2016USD ($)
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	$ 49,433,000
Maximum Exposure to Loss	68,045,000
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	41,233,000
Maximum Exposure to Loss	48,094,000
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	8,200,000
Maximum Exposure to Loss	$ 19,951,000

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 50
Commitment funded	43.1
Funding commitments	$ 6.9
Beneficial ownership in common stock	10.90%	10.90%
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 20
Commitment funded	8.2
Funding commitments	$ 11.8
Beneficial ownership in common stock	2.30%	2.30%

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Segment (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Goodwill [Line Items]
Beginning Balance	$ 719,740
Impairment	(23,147)
Impact of foreign currency fluctuations and other	(5,152)
Ending Balance	691,441
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	602,106
Impact of foreign currency fluctuations and other	(9,765)
Ending Balance	592,341
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,634
Impairment	(23,147)
Impact of foreign currency fluctuations and other	4,613
Ending Balance	$ 99,100

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) $ in Millions	Sep. 30, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses	$ 23.1

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2016USD ($)Derivative	Dec. 31, 2015USD ($)	Jun. 03, 2015USD ($)Agreement
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Derivative	9
Notional amount	$ 118,800,000
Losses related to these foreign exchange forward contracts	$ 8,600,000	$ 5,200,000
Expiration description of hedge instruments	2016 and the first six months of 2017
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Agreement			7
Notional amount			$ 440,000,000
Interest swaps accrual beginning date	Jun. 3, 2015
Derivative fixed interest rate	2.10%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net	$ 5,300,000
Interest Rate Swaps [Member] | Fixed Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Interest Rate Swaps [Member] | Variable Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Seven Interest Rate Swaps [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2017
Seven Interest Rate Swaps [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2020

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - Designated as Hedging Instrument [Member] - Other Current Liabilities [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 8,564	$ 5,194
Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 14,186	$ 5,698

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 8,040	$ (8,336)	$ (8,758)	$ 1,315
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	3,668	(3,795)	(3,370)	2,594
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 4,372	$ (4,541)	$ (5,388)	$ (1,279)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] $ in Thousands	Sep. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 40,286
Fair value of liabilities	27,250
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	8,564
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	14,186
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,500
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	40,286
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	22,750
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	8,564
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	14,186
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,500
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,500
Available-for-sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	408
Available-for-sale Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	408
Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	39,878
Trading Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 39,878

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable and Accrued Expenses [Member] - Contingent Consideration [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 4,374	$ 1,452
Revaluations included in earnings	126	6,002
Ending Balance, Contingent Consideration	$ 4,500	$ 7,454

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$ 346,816	$ 368,106
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,106,000
Cost and equity method investments	67,800
Goodwill	691,400
Other identifiable intangibles, net	$ 346,800

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Detail) - Equity Repurchase Program [Member] $ / shares in Units, $ in Millions	9 Months Ended	35 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)
Class Of Stock [Line Items]
Repurchase of stock, value		$ 678.2
Equity available for repurchase under the repurchase program	$ 46.8	46.8
Common Stock [Member]
Class Of Stock [Line Items]
Repurchase of stock, shares | shares	1,486,679
Repurchase of stock, average market price per share | $ / shares	$ 65.67
Repurchase of stock, value	$ 97.6	619.1
Stock Options [Member]
Class Of Stock [Line Items]
Repurchase of stock, value		$ 59.1

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of Non-controlling Interests (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Equity [Abstract]
Beginning Balance			$ 228,536	$ 49
Investment by non-controlling interest			1,274	231,030
Comprehensive income (loss):
Net income (loss)	$ 4,807	$ (2,447)	11,704	(2,418)
Foreign currency adjustments, net of income tax			(10,009)	(2,566)
Ending Balance	$ 231,505	$ 226,095	$ 231,505	$ 226,095

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended	21 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ (467,000)	$ 11,984,000	$ 27,791,000	$ 23,542,000
Quest [Member]
Restructuring Cost and Reserve [Line Items]
Severance, facility closure and other exit-related costs					$ 14,000,000
2016 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved	$ 41,000,000		41,000,000			$ 41,000,000
2016 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			22,300,000
2016 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			2,200,000
2016 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 2,100,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved					$ 30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						12,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member] | Quest [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						9,600,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						8,900,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs						$ 952,000

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			$ 13,564
Expense, net of reversals	$ (467)	$ 11,984	27,791	$ 23,542
Payments			(25,077)
Foreign currency translation and other			(1,031)
Restructuring reserves, ending balance	15,247		15,247
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			12,179
Expense, net of reversals			26,470
Payments			(23,419)
Foreign currency translation and other			(1,858)
Restructuring reserves, ending balance	13,372		13,372
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			1,385
Expense, net of reversals			1,321
Payments			(1,658)
Foreign currency translation and other			827
Restructuring reserves, ending balance	$ 1,875		$ 1,875

Merger Related Costs - Addition

Merger Related Costs - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Business Combinations [Abstract]
Merger related costs	$ 3,747	$ 12,689

Impairment Charges - Additional

Impairment Charges - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Impairment Of Goodwill And Intangible Assets [Line Items]
Goodwill impairment loss	$ 23,147
Encore [Member]
Impairment Of Goodwill And Intangible Assets [Line Items]
Goodwill impairment loss	23,100
Identifiable intangible assets impairment loss	$ 4,800

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 4,491	$ 3,554	$ 13,122	$ 11,419
Interest cost	891	867	2,741	2,600
Expected return on plan assets	(805)	(869)	(2,549)	(2,583)
Amortization of actuarial losses	229	225	661	680
Total pension expense related to defined benefit plans	$ 4,806	$ 3,777	$ 13,975	$ 12,116

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016USD ($)Position	Dec. 31, 2015USD ($)
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$ 2,435,000	$ 3,337,000
Number of positions expected to be eliminated | Position	270
Severance expense, net of reversals	$ (513,000)
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	$ (513,000)

Employee Benefit Plans - Summ65

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$ 3,337
Severance expense, net of reversals	(513)
Severance payments	(344)
Severance foreign currency translation	(45)
Severance expenses payable, ending balance	$ 2,435

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ (564,217)
Ending Balance	(313,432)
Beginning Balance	33,428
Other comprehensive (loss) income before reclassifications, tax	12,869
Reclassification adjustments, tax	(4,377)
Ending Balance	41,920
Other comprehensive (loss) income before reclassifications, net of tax	(43,488)
Reclassification adjustments, net of tax	13,878
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(116,830)
Other comprehensive (loss) income before reclassifications, before tax	(30,272)
Ending Balance	(147,102)
Available-for-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(708)
Other comprehensive (loss) income before reclassifications, before tax	12
Ending Balance	(696)
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,992)
Other comprehensive (loss) income before reclassifications, before tax	(26,352)
Reclassification adjustments, before tax	17,594
Ending Balance	(22,750)
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,264)
Other comprehensive (loss) income before reclassifications, before tax	255
Reclassification adjustments, before tax	661
Ending Balance	(12,348)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(111,366)
Ending Balance	$ (140,976)

Comprehensive Income - Summar67

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 7,662	$ 3,989	$ 17,594	$ 14,573
Income tax benefit	1,713	1,377	4,144	4,623
Total net of income taxes	5,949	2,612	13,450	9,950
Amortization of actuarial losses	229	225	661	680
Total before income taxes	229	225	661	680
Income tax benefit	82	83	233	251
Total net of income taxes	147	142	428	429
Interest Rate Swaps [Member] | Interest Expense [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	1,600	3,130	4,700	9,233
Foreign Exchange Forward Contracts [Member] | Service Revenues [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 6,062	$ 859	$ 12,894	$ 5,340

Segments - Additional Informati

Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Service revenues	$ 1,136,423	$ 1,093,480	$ 3,411,509	$ 3,197,820
Costs of revenue, service costs	703,791	683,058	2,144,996	2,028,730
Selling, general and administrative expenses	233,645	231,415	700,787	676,919
Income from operations	167,770	167,023	497,309	468,629
Restructuring costs	467	(11,984)	(27,791)	(23,542)
Merger related costs	(3,747)		(12,689)
Impairment charges	(27,937)		(27,937)
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues	874,312	810,045	2,601,909	2,345,971
Costs of revenue, service costs	499,638	461,858	1,513,353	1,352,730
Selling, general and administrative expenses	167,732	166,758	505,378	478,643
Income from operations	206,942	181,429	583,178	514,598
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues	262,111	283,435	809,600	851,849
Costs of revenue, service costs	204,153	221,200	631,643	676,000
Selling, general and administrative expenses	35,172	38,186	111,422	114,953
Income from operations	22,786	24,049	66,535	60,896
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative expenses	30,741	26,471	83,987	83,323
Income from operations	$ (30,741)	$ (26,471)	$ (83,987)	$ (83,323)

Segments - Depreciation and Amo

Segments - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 34,603	$ 32,884	$ 98,368	$ 93,224
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	29,593	26,681	82,575	74,110
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	4,020	5,118	12,549	15,497
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 990	$ 1,085	$ 3,244	$ 3,617

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Stock-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	916	1,003	1,359	1,076
Performance Conditions [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	198	51	161	40
Share-Based Awards [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	718	952	1,198	1,036

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) shares in Millions	Nov. 01, 2016USD ($)	Oct. 03, 2016USD ($)shares	Sep. 30, 2016USD ($)	Sep. 28, 2016USD ($)	Sep. 28, 2016EUR (€)	Dec. 31, 2015USD ($)
Subsequent Event [Line Items]
Goodwill			$ 691,441,000			$ 719,740,000
Estimated additional income tax liability			$ 175,000,000
Subsequent Event [Member] | Equity Repurchase Program [Member]
Subsequent Event [Line Items]
Equity repurchase program increase in authorized amount	$ 1,500,000,000
Equity repurchase program authorized amount	1,546,800,000
Subsequent Event [Member] | Senior Secured Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Debt instrument principal amount		$ 1,000,000,000
Accelerated maturity date under certain circumstances		2,020
Subsequent Event [Member] | Senior Secured Revolving Credit Facility [Member] | U.S Dollars [Member]
Subsequent Event [Line Items]
Debt instrument principal amount		$ 450,000,000
Subsequent Event [Member] | Senior Secured Revolving Credit Facility [Member] | US Dollars, Euros, Swiss Francs and other foreign currencies [Member]
Subsequent Event [Line Items]
Debt instrument principal amount		400,000,000
Subsequent Event [Member] | Senior Secured Revolving Credit Facility [Member] | US Dollars and Yen [Member]
Subsequent Event [Line Items]
Debt instrument principal amount		150,000,000
Subsequent Event [Member] | 6% Senior Notes due 2020
Subsequent Event [Line Items]
Repayment of debt	$ 500,000,000
Debt instrument interest rate	6.00%
Subsequent Event [Member] | Term Loans [Member] | Senior Secured Credit Facilities [Member]
Subsequent Event [Line Items]
Repayment of debt		1,389,400,000
Subsequent Event [Member] | Term A loans due 2019 [Member]
Subsequent Event [Line Items]
Debt instrument principal amount		884,000,000
Subsequent Event [Member] | Term A loan facility due in 2021 [member]
Subsequent Event [Line Items]
Debt instrument principal amount		$ 1,350,000,000
Subsequent Event [Member] | Term A Loan [Member]
Subsequent Event [Line Items]
Accelerated maturity date under certain circumstances		2,020
IMS Health Holdings, Inc. [Member] | Unsecured Senior Notes [Member] | 2016 Notes [Member]
Subsequent Event [Line Items]
Debt instrument principal amount				$ 1,750,000,000
IMS Health Holdings, Inc. [Member] | Unsecured Senior Notes [Member] | 5% Dollar Notes [Member]
Subsequent Event [Line Items]
Debt instrument principal amount				$ 1,050,000,000
Debt instrument interest rate				5.00%	5.00%
Debt instrument maturity date			Oct. 15, 2026
Debt instrument interest payment terms			interest payable semi-annually on April 15 and October 15 of each year, beginning on April 15, 2017.
Debt instrument frequency of periodic interest payment			semi-annually
Debt instrument date of first interest payment			Apr. 15, 2017
IMS Health Holdings, Inc. [Member] | Unsecured Senior Notes [Member] | 3.5% Euro Notes [Member]
Subsequent Event [Line Items]
Debt instrument principal amount | €					€ 625,000,000
Debt instrument interest rate				3.50%	3.50%
Debt instrument maturity date			Oct. 15, 2024
Debt instrument interest payment terms			interest payable semi-annually on April 15 and October 15 of each year, beginning on April 15, 2017.
Debt instrument frequency of periodic interest payment			semi-annually
Debt instrument date of first interest payment			Apr. 15, 2017
IMS Health Holdings, Inc. [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business acquisition through merger, acquisition date		Oct. 3, 2016
Estimated fair value of acquired assets		$ 10,000,000,000
Estimated fair value of identifiable tangible and intangible assets		10,000,000,000
Estimated fair value of liabilities assumed		9,000,000,000
Goodwill		$ 9,000,000,000
IMS Health Holdings, Inc. [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Merger agreement, stock for stock exchange ratio		38.40%
Business acquisition through merger, consideration in stock		$ 10,400,000,000
Business acquisition through merger, consideration in stock, shares issued | shares		126.6

Subsequent Events - Summary of

Subsequent Events - Summary of Pro Forma Results (Detail) - IMS Health Holdings, Inc. [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Subsequent Event [Line Items]
Product and service revenues	$ 1,926,000	$ 1,828,000	$ 5,775,000	$ 5,305,000
Reimbursed expenses	361,000	331,000	1,128,000	1,018,000
Total revenues	2,287,000	2,159,000	6,903,000	6,323,000
Net income attributable to Quintiles IMS Holdings, Inc.	$ 88,000	$ 113,000	$ 255,000	$ 525,000
Earnings per share attributable to common stockholders:
Basic	$ 0.36	$ 0.45	$ 1.04	$ 2.10
Diluted	$ 0.35	$ 0.44	$ 1.02	$ 2.04